Schrodinger(SDGR) - 2022 Q4 - Earnings Call Presentation

Enhanced Platform Capabilities • Initiated SGR-1505 Phase 1 trial Second Quarter 2022 Supplemental Slides February 28, 2023 Transforming Discovery of Therapeutics and Materials This presentation contains certain "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this presentation, including, without limitation, statements regarding ...